PRANA BIOTECHNOLOGY
PRANA BIOTECHNOLOGY operates in Diversified Metals & Mining.
PRANA BIOTECHNOLOGY (PBN) - Total Assets
Latest total assets as of June 2024: €19.22 Million EUR
Based on the latest financial reports, PRANA BIOTECHNOLOGY (PBN) holds total assets worth €19.22 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PRANA BIOTECHNOLOGY - Total Assets Trend (2016–2024)
This chart illustrates how PRANA BIOTECHNOLOGY’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PRANA BIOTECHNOLOGY - Asset Composition Analysis
Current Asset Composition (June 2024)
PRANA BIOTECHNOLOGY's total assets of €19.22 Million consist of 99.0% current assets and 1.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 65.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how PRANA BIOTECHNOLOGY's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PRANA BIOTECHNOLOGY's current assets represent 99.0% of total assets in 2024, a decrease from 99.8% in 2016.
- Cash Position: Cash and equivalents constituted 65.8% of total assets in 2024, down from 84.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PRANA BIOTECHNOLOGY Competitors by Total Assets
Key competitors of PRANA BIOTECHNOLOGY based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
PRANA BIOTECHNOLOGY - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PRANA BIOTECHNOLOGY generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PRANA BIOTECHNOLOGY is currently not profitable relative to its asset base.
PRANA BIOTECHNOLOGY - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.54 | 6.17 | 5.98 |
| Quick Ratio | 3.54 | 6.17 | 5.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €13.66 Million | € 22.67 Million | € 16.54 Million |
PRANA BIOTECHNOLOGY - Advanced Valuation Insights
This section examines the relationship between PRANA BIOTECHNOLOGY's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -29.6% |
| Total Assets | €19.22 Million |
| Market Capitalization | $50.10 USD |
Valuation Analysis
Below Book Valuation: The market values PRANA BIOTECHNOLOGY's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PRANA BIOTECHNOLOGY's assets decreased by 29.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PRANA BIOTECHNOLOGY (2016–2024)
The table below shows the annual total assets of PRANA BIOTECHNOLOGY from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €19.22 Million | -29.63% |
| 2023-06-30 | €27.32 Million | -33.96% |
| 2022-06-30 | €41.36 Million | +23.16% |
| 2021-06-30 | €33.59 Million | +238.99% |
| 2020-06-30 | €9.91 Million | -50.24% |
| 2019-06-30 | €19.91 Million | +6.32% |
| 2018-06-30 | €18.73 Million | -25.93% |
| 2017-06-30 | €25.28 Million | -25.04% |
| 2016-06-30 | €33.73 Million | -- |